Articles by EAG Life Sciences - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by EAG Life Sciences

EAG Life Sciences


Articles
Extractables and Leachables for Pharmaceuticals and Medical Devices
November 27, 2012

Extractables and Leachable (E&L) studies challenge our industry due to their late stage occurrence and investigational nature. This white paper defines Extractables and Leachables and outlines an E&L study plan that is both scientifically relevant and compliant within GXP regulatory systems.

Elemental Impurities: Navigating the Proposed Regulations of USP <232> and <233>
November 1, 2012

The implementation of the proposed chapters USP chapters on elemental impurities, <232> and <233> is best suited to the use of closed vessel digestion and analysis by an ICP analytical technique. This paper addresses the challenges involved, as well as appropriate methods, procedures, and limits associated with this analysis.

Robust Analytical Methods for Genotoxic Impurities
September 25, 2012

Genotoxic Impurities and Potential Genotoxic Impurities (GIs, PGIs) pose analytical method development and validation challenges for pharmaceutical development. This white paper illustrates overcoming specificity and low limits of detection difficulties for quantitative analysis of Genotoxic Impurities and Potential Genotoxic Impurities for methyl, ethyl and isopropyl camphor sulfonate esters in a drug substance.

Extractables and Leachables for Pharmaceuticals and Medical Devices
July 31, 2012

Extractables and Leachables (E&L) studies challenge our industry due to their late stage occurrence and investigational nature. This white paper defines Extractables and Leachables and outlines an E&L study plan that is both scientifically relevant and compliant within GXP regulatory systems.

Robust Analytical Methods for Genotoxic Impurities
June 26, 2012

The reactive nature of genotoxic impurities and potential genotoxic impurities poses unique analytical method development and validation challenges. This case study illustrates a difficult development and validation for quantitative analysis of genotoxic impurities and potential genotoxic impurities for methyl, ethyl and isopropyl camphor sulfonate esters in a drug substance.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Click here